Lilly launches phase III trial of targeted cancer agentThis is a featured page

Source: Europa Press

Date: 03/09/06

Headline: Lilly launches phase III trial of targeted cancer agent

One of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli Lilly and Company today. Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.


Louise
Louise 		Latest page update: made by Louise , Mar 9 2006, 11:20 AM EST (about this update About This Update Louise Rename - Louise

No content added or deleted.
- complete history)
Keyword tags: apoptosis brain cancer chemotherapy Colorectal cancer enzastaurin glioblastoma Lung cancer mantle cell lymphoma non-Hodgkin's lymphoma oral agent Pancreatic cancer relapse research Tumor
More Info: links to this page

Threads for this page

There are no threads for this page.  Be the first to start a new thread.

Related Content

  (what's this?Related ContentThanks to keyword tags, links to related pages and threads are added to the bottom of your pages. Up to 15 links are shown, determined by matching tags and by how recently the content was updated; keeping the most current at the top. Share your feedback on Wetpaint Central.)
The Memory Wall Understanding cancer Robert Vestal, Jr.
Colon cancer Non-hodgkin's lymphoma Coping with fear
Managing the Side Effects of Chemotherapy and Radiation Therapy Cancer News, Cancer Research A Love Affair with Cancer
The wikiCancer Resource Guide CANCER DOCTOR IS SAVING LIVES! - PLEASE PASS THIS ALONG - >>>>>> Started with wicked Headaches